Literature DB >> 32895628

Recurrent pneumothorax in a COVID-19 patient: A case report.

Rodrigo A S Sardenberg1,2, João Pedro E Sant'Ana3, Amanda O Vicente3, Amanda S Pereira3, Pedro V Bertozzi3, Rafaela B C Mano3.   

Abstract

An 88-year-old woman diagnosed with COVID-19 in Brazil presented with recurrent pneumothorax. She was under mechanical ventilation for 20 days because of acute respiratory distress syndrome (ARDS). Chest x-ray revealed right lung pneumothorax, which was treated with a pigtail chest tube leading to successful lung reexpansion. After 48 hours the patient developed an ipsilateral pneumothorax and a new tube thoracostomy under conventional chest tube under suction was performed and kept in place for 14 days. This brief report highlights that the conventional chest tube under suction procedures might be a good choice in Covid-19 patients.
© 2020 The Author(s).

Entities:  

Keywords:  COVID-19; Chest drainage; Pneumothorax

Year:  2020        PMID: 32895628      PMCID: PMC7462578          DOI: 10.1016/j.rmcr.2020.101201

Source DB:  PubMed          Journal:  Respir Med Case Rep        ISSN: 2213-0071


Introduction

Recently, a cluster of atypical pneumonia originated in Wuhan, China, with the first known case recorded on December 1st, 2019. On March 11th, 2020, the World Health Organization (WHO) declared the outbreak of COVID-19 as a pandemic [1,2]. The first case in Brazil was confirmed on February 26th, 2020, and since then the country has seen exponential increase in case numbers. The symptoms vary in intensity and severity, from asymptomatic to lethal cases, leading to different outcomes [2]. To date, there have been few reports of pneumothorax as a complication associated with COVID-19. We report a case in which the patient presented a recurrent pneumothorax treated with conventional chest tube under suction.

Results

An 88-year-old woman diagnosed with COVID-19 at a hospital in São Paulo - the epicenter of the COVID-19 outbreak in Brazil – was put under mechanical ventilation for 20 days due to acute respiratory distress syndrome (ARDS) caused by the SARS-CoV-2. The patient had no history of smoking. Laboratory examination revealed a high percentage of white blood cell neutrophil count 12,870 (normal range: 1700–7000 mm3) and a decreased percentage lymphocyte count 860 (normal range: 900–2900 mm3). There were elevated blood levels for C-reactive protein 28.05 mg/L (normal range: 0–5 mg/L), D-dimer 4.65 mg/L (normal range: < 0.5 mg/L), and Lactic Dehydrogenase (LDH) 595 U/L (normal range: 240–480 U/L). At a fraction of inspired O2 (FiO2) of 60%, with a PEEP of 8 mmHg under a 20 mmHg pressure support, the blood gas analysis showed pH 7.49 (normal 7.35–7.45) a PO2 of 89 mmHg (normal 80–100 mmHg), pCO2 of 28 mmHg (normal 35–45 mmHg) and a SatO 2 of 97% (normal 94–100%). Suddenly, she developed oxygen desaturation (SpO 2) of 87% and a worse respiratory pattern. During physical examination, respiratory sounds were diminished at right hemithorax. The chest x-ray revealed right pneumothorax (Fig. 1-A). A pigtail catheter was introduced with successful reexpansion of the right lung (Fig. 1-B). A huge air escape was observed after the pleural drainage, which was put under a water seal with a filter protected.
Fig. 1

Chest X-Rays of an 88-year-old woman with COVID-19

A. Chest X-Ray shows right pneumothorax B. A pigtail catheter on the right hemithorax and lung reexpansion C. recurrent ipsilateral pneumothorax D. Lung reexpansion after conventional chest tube.

Chest X-Rays of an 88-year-old woman with COVID-19 A. Chest X-Ray shows right pneumothorax B. A pigtail catheter on the right hemithorax and lung reexpansion C. recurrent ipsilateral pneumothorax D. Lung reexpansion after conventional chest tube. Forty-eight hours after the first pneumothorax, the patient developed another respiratory distress, with an ipsilateral new pneumothorax (Fig. 1-C) requiring another chest drain with conventional 28F chest tube thoracostomy under suction, leading to improved lung reexpansion (Fig. 1-D). The pigtail was withdrawn two days after the chest tube insertion, and the chest tube was kept in place until mechanical ventilation weaning, which occurred 14 days after the second procedure.

Discussion

Recent studies suggest that pneumothorax is a rare complication, found in 1–2% of COVID-19 patients with a mean time occurrence of 24.3 days from the hospital admission during the early phase of intubation [3,4]. Also, reported cases have shown that spontaneous pneumomediastinum may occur in 12% of SARS patients sometimes not related to pneumothorax [5]. Mechanical ventilation associated with pulmonary fibrosis could cause pulmonary bullae. Variations on the intrapulmonary pressure could result in bullae rupture, leading to a secondary pneumothorax [6]. The patient presented high levels of leukocytes, neutrophils, and LDH, some studies have drawn a parallel between all these findings and COVID-19 pneumothoraces [5,7]. Pneumothorax diagnosis presents clinical manifestations - especially in patients under mechanical ventilation - such as a sudden increase in dyspnea and rapid oxygen desaturation, confirmed by imaging exams [5]. Improvement on therapeutic effect and reduction in mortality can be achieved with early diagnosis and timely treatment [8]. This complication may be associated with poorer pulmonary prognosis, especially among COVID-19 patients [9]. The chest drainage, a potentially viral transmitter, offered short-term stabilization of clinical signs, ensuring adequate lung expansion [5,10]. To avoid aerosolization from conventional chest tube, it is recommended closed drainage systems connecting the standard tube bottle to wall suction, as was used in our case [10]. We advocate the use of the conventional chest tube instead of pigtail catheter for high debt fistulae, as it minimizes aerosol and can be used under suction, which allows a faster fistulae recovery.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of competing interest

The authores declare that there were no conflicts of interest regarding the article.
  7 in total

1.  Radiology Perspective of Coronavirus Disease 2019 (COVID-19): Lessons From Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome.

Authors:  Melina Hosseiny; Soheil Kooraki; Ali Gholamrezanezhad; Sravanthi Reddy; Lee Myers
Journal:  AJR Am J Roentgenol       Date:  2020-02-28       Impact factor: 3.959

2.  Management of Persistent Pneumothorax With Thoracoscopy and Bleb Resection in COVID-19 Patients.

Authors:  Alberto Aiolfi; Tullio Biraghi; Andrea Montisci; Gianluca Bonitta; Giancarlo Micheletto; Francesco Donatelli; Silvia Cirri; Davide Bona
Journal:  Ann Thorac Surg       Date:  2020-04-27       Impact factor: 4.330

3.  Chest tube with air leaks is a potential "super spreader" of COVID-19.

Authors:  Hiroshi Sugimoto; Takuya Kohama
Journal:  Am J Infect Control       Date:  2020-06-05       Impact factor: 2.918

4.  Severe acute respiratory syndrome complicated by spontaneous pneumothorax.

Authors:  Alan D L Sihoe; Randolph H L Wong; Alex T H Lee; Lee Sung Lau; Natalie Y Y Leung; Kin Ip Law; Anthony P C Yim
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

5.  Mediastinal Emphysema, Giant Bulla, and Pneumothorax Developed during the Course of COVID-19 Pneumonia.

Authors:  Ruihong Sun; Hongyuan Liu; Xiang Wang
Journal:  Korean J Radiol       Date:  2020-03-20       Impact factor: 3.500

6.  SARS, pneumothorax, and our response to epidemics.

Authors:  Gregory A Filice
Journal:  Chest       Date:  2004-06       Impact factor: 9.410

Review 7.  Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2.

Authors:  Damian N Valencia
Journal:  Cureus       Date:  2020-03-24
  7 in total
  1 in total

1.  Risk Factors, Clinical Characteristics, and Outcome of Air Leak Syndrome in COVID-19: A Systematic Review.

Authors:  Abhishek Singh; Yudhyavir Singh; Neha Pangasa; Puneet Khanna; Anjan Trikha
Journal:  Indian J Crit Care Med       Date:  2021-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.